Jiangsu Kangyuan Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. It is a national key high-tech enterprise, a national technological innovation demonstration enterprise, and one of the top 100 enterprises in China's pharmaceutical industry (No. 29th), the fifth among the top ten traditional Chinese medicine companies in the country, the top 20 innovative Chinese pharmaceutical companies, and currently has more than 5,000 employees. It has established several national-level scientific research platforms such as the "National Key Laboratory of New Technology in Traditional Chinese Medicine Pharmaceutical Processes". In 2018, the laboratory was rated as "National Key Laboratory of Excellent Enterprises" (first in the pharmaceutical field). It has obtained 47 national-level new traditional Chinese medicines and 331 invention patent authorizations; undertaken more than 50 scientific and technological projects; won 1 second-class national technological invention award, 2 second-class national scientific and technological progress awards, and 8 first-class provincial and ministerial scientific and technological progress awards. (including 2 first prizes for Jiangsu Provincial Science and Technology Progress Awards); its R&D strength has ranked first in the "Traditional Chinese Medicine R&D Strength Ranking" for three consecutive years. Guizhi Fuling Capsule has completed Phase II clinical trials in the United States and is a model variety for the internationalization of Chinese traditional medicine in my country.